Published Aug 08, 2018

Harbour BioMed inks $350 million deal for rights to A167

Member News

Related or similar articles

March 26, 2019

Abcuro announces pre-clinical data on new immuno-oncology target

First in vivo validation of KLRG1 as a new cancer immunotherapy target
Member News
October 9, 2024

Explore Labshares' Latest High-Tech Equipment Advancements

Labshares News
June 18, 2024

Labshares Announces Key Leadership Additions: Devon Lagasse Joins as VP of Growth and Emma Orfanos Is Promoted to Manager of Business Development

Press Releases